Microalbuminuria and early endothelial activation in essential hypertension

Journal of Human Hypertension

Volumn 21, Issue 2, 2007, Pages 167-172

  Cottone, S ^a   Mule G ^a   Nardi, E ^a   Lorito, M C ^a   Guarneri, M ^a   Arsena, R ^a   Briolotta, C ^a   Vadala A ^a   Cerasola, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOCHEMICAL MARKER; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ECHOGRAPHY; ESSENTIAL HYPERTENSION; HUMAN; MAJOR CLINICAL STUDY; MICROALBUMINURIA; MULTIPLE REGRESSION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

ADULT; ALBUMINURIA; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; REGRESSION ANALYSIS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 33847039953     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002109     Document Type: Article

References (36)

1. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on endothelin and endothelial factors of the European Society of Hypertension. J Hypertension 2005; 23: 7-17.
2. Smith SJ. The role of integrin-mediated cell adhesion in health and disease: Integrin based therapy in clinical medicine. Ann Intern Med 2000; 132: 333-336.
3. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809.
4. Malek AM, Alper SL, Izumo S. Haemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282: 2035-2042.
5. Taddei S, Virdis A, Mattel P, Salvetti A. Aging and endothelial function in normotensive subjects and essential hypertensive patients. Circulation 1995; 91: 1981-1987.
6. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. JACC 1999; 34: 631-637.
7. Blann AD, Naqvi T, Waite MA, McCollum CM. Von Willebrand factor and endothelial damage in essential hypertension. J Human Hypertens 1993; 7: 107-111.
8. Cottone S, Vadalà A, Vella MC, Panepinto N, Cerasola G. Comparison of tumour necrosis factor and endothelin-1 between essential and renal hypertensives. J Human Hypertens 1998; 12: 351-354.
9. Cottone S, Mulè G, Nardi E, Vadalà A, Guarneri M, Cerasola G. Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens 2006; 19: 313-318.
10. Pedrinelli R, Giampiero O, Carmassi F, Melillo E, Dell'Omo G, Catapano G et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18.
11. Cottone S, Vadalà A, Mangano MT, Riccobene R, Mulè G, Vella MC et al. Endothelium-derived factors in microalbuminuric and non-microalbuminuric essential hypertensives. Am J Hypertension 2000; 13: 172-176.
12. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Sharling H et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension and diabetes. Circulation 2004; 110: 32-35.
13. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension - Guidelines Committee. Journal of Hypertens 2003; 21: 1011-1105.
14. De Kossodo S, WHO Collaborative Study Group. Assaying tumour necrosis factor concentration in human serum. A WHO International Collaborative Study. J Immunol Methods 1995; 182: 107-111.
15. Armitage P, Berry G. Statistical Methods in Medical Research, 2nd edn, Blackwell Scientific Publications: Oxford, 1987, pp 304-312.
16. Anderson TJ, Gerhard MD, Meredith IT. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75: 71B-74B.
17. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998; 29: 2129-2135.
18. De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2646-2654.
19. Ikata J, Wakatsuki T, Oishi Y, Oki T, Ito S. Leukocyte counts and concentrations of soluble adhesion molecules as predictors of coronary atherosclerosis. Coron Artery Dis 2000; 11: 445-449.
20. Blankeberg S, Rupprechy HJ, Bickel C, Peetz D, Hafner G, Tiret IJ. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-1342.
21. Malmqvist K, Wallen HN, Held C, Kahan T. Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens 2002; 20: 1563-1569.
22. Rosenson RS, Koenig W. High-sensitivity CRP and cardiovascular risk in CHD patients. Curr Opin Cardiol 2002; 17: 325-331.
23. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
24. Sesso H, Buring J, Rifai N, Blage G, Cazano J, Ridker PM. C reactive protein and risk for developing hypertension. JAMA 2003; 290: 2945-2951.
25. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-861.
26. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429-433.
27. Cerasola G, Cottone S, Mulè G, Mangano MT, Contorno A, LiVecchi M et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 15: 915-919.
28. Hillege HL, Fidler V, Diercks G, van Gilst W, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
29. Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al., for the investigator of HOPE Study. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. JAMA 2001; 286: 421-426.
30. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 2005; 112: 969-975.
31. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: Association with incident coronary heart disease and death. Hypertension 2005; 46: 1-5.
32. De Caterina R, Ghiadoni L, Taddei S, Virdis A, Almerigogna F, Basta G et al. Soluble E-selectin in essential hypertension: A correlate of vascular structural changes. Am J Hypertension 2001; 14: 259-266.
33. Bigazzi R, Bianchi S, Campese VM. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implication. Am J Kidney Dis 1999; 34: 973-995.
34. Mulè G, Cottone S, Vadalà A, Volpe V, Mezzatesta G, Mongioví R et al. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med 2004; 256: 22-29.
35. Klausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rassmussen B. Plasma concentration of VCAM-1 and ICAM-1 are elevated in patients with type 2 diabetes mellitus with microalbuminuria or overt nephropathy. Diabet Med 2000; 17: 644-649.
36. Koga M, Otsuki M, Kubo M, Hashimoto J, Kasayama S. Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. Diabet Med 1998; 15: 661-667.